CSF3 and amyotrophic lateral sclerosis: The pharmacokinetics of G‐CSF administration has been extensively studied in humans, and the therapeutic window, in terms of achieving HSC mobilization, can extend beyond twice the recommend dose.55 Furthermore, monthly administrations of mobilizing agents have been shown to be safe in a trial for amyotrophic lateral sclerosis.19 This has provided early safety data on the use of G‐CSF for neurodegenerative conditions.